Novo Nordisk A/S (ADR) (NVO) is playing to the underlying trends and changes in the health care sector as the world leader in diabetic care, with the broadest product portfolio in the health care industry, says Eric Kallen, President and Chief Investment Strategist at Hayek Kalen Investment.
“This sector is seeing a tremendous amount of change. Change is being imposed in part by new regulations, but also by changes in demographics…The demographic changes are more attractive to us. Globally, the population is aging and we are living longer. Coupled with this is the fact that health care continues to be a larger and larger component of GDP,” Kallen said.
FOR MORE INFORMATION ABOUT THIS INTERVIEW CLICK HERE.
Kallen believes that NVO is a great way to invest in the current health care trends, as diabetes continues to grow worldwide and NVO stands as the world leader in diabetic care.
“A company like Novo Nordisk as a great way to invest in these underlying trends. NVO is a Danish drug company that focuses on diabetes. Given the trends that I just mentioned, coupled with the fact that obesity has really begun to take its toll, diabetes is what we would consider to be a growth disease. Globally, there are nearly 300 million people who suffer from diabetes, and in China, where 114 million Chinese have the disease, it has reached epidemic status. Novo Nordisk is the world leader in diabetes care, and it has the broadest diabetes product portfolio in the industry,” Kallen said.
Long-Term Earnings Growth for Nestle SA (ADR) (OTCMKTS:NSRGY) and Danone SA (ADR) (OTCMKTS:DANOY)
May 26, 2016
Dipexium Pharmaceuticals Inc (DPRX) Expects to be Standard of Care in Mild Diabetic Foot Infections
May 05, 2015
YY Inc (ADR) (YY) a Leader in Chinese Online Music Market Overlooked by U.S. Investors
May 20, 2014
Alaina Anderson is the William Blair International Leader ADR Portfolio Manager
February 02, 2021
